Skip to main content

Table 1 Characteristics of patients who underwent LT. Data is given as mean (± SD), median (range) or number (%), as appropriate

From: Prevalence of human herpesviruses in biliary fluid and their association with biliary complications after liver transplantation

Number of patients

73

Gender recipient, female

15 (20.5%)

Gender donor, female

36 (49.3%)

Recipient age, years, (median, range)

56 (30–69)

Donor age, years, (median, range)

67 (21–88)

Follow-up, months, (median, range)

48 (2–102)

Child-Turcotte-Pugh score (A/B/C) at LT, n

25/16/31

Valganciclovir prophylaxis at time of ERC

34 (47.1%)

Time of ERC, months since LT, (median, range)

3.4 (0.3–73)

Lab/eMELD at LT (mean ± SD)

27.0 ± 8.7

Cold ischemia time, hours (mean ± SD)

10.0 ± 2,64

Indication

 Alcoholic cirrhosis

23 (31.5%)

 Hepatitis B

2 (2.7%)

 Hepatitis C

11 (15.1%)

 HCC

15 (20.5%)

 PSC

2 (2.7%)

 Cryptogenic

7 (9.6%)

 Other

13 (17.8%)

Death during follow-up

11 (15.1%)

Retransplantation

16 (21.9%)

Ciclosporin de novo

51 (69.9%)

Tacrolimus de novo

20 (27.4%)

Mycophenolate mofetil

61 (83.6%)

Anastomotic stricture

34 (46.6%)

Non-anastomotic stricture

37 (50.7%)

Acute rejection

19 (26.0%)

  1. de novo: administered directly after LT; eMELD exceptional model of end-stage liver disease, ERC endoscopic retrograde cholangiopancreatography, HHC hepatocellular carcinoma, LT liver transplantation, labMELD laboratory model of end-stage liver disease, PSC primary sclerosing cholangitis